|

Intent of Surgery for IPMN

RECRUITINGSponsored by NYU Langone Health
Actively Recruiting
SponsorNYU Langone Health
Started2025-09-15
Est. completion2025-12
Eligibility
Age18 Years+
Locations8 sites
View on ClinicalTrials.gov →

NCT07216521

Summary

This multicenter retrospective observational cohort study seeks to: 1. Classify surgical intent in patients with resected Intraductal Papillary Mucinous Neoplasms (IPMN) and quantify the proportion of IPMN-associated cancers diagnosed as overt pancreatic cancer with incidental IPMN association on pathology. 2. Compare clinicopathologic features and outcomes between surveillance-detected and incidentally detected IPMN-derived pancreatic cancers. 3. Revise and redefine risk features limited to patients undergoing surgery for IPMN-related indications, identifying optimal predictors of malignant IPMN (high-grade dysplasia or invasive cancer).

Eligibility

Age: 18 Years+
Inclusion Criteria:

* All patients (18 years old of greater) who underwent surgical resection for IPMN (including low-, high-grade dysplasia, or invasive carcinoma) between July 1, 2015 and July 1, 2025.

Exclusion Criteria:

* Patients with concomitant pancreatic ductal adenocarcinoma (PDAC)

Conditions2

CancerIntraductal Papillary Mucinous Neoplasm

Locations8 sites

Mayo Clinic
Phoenix, Arizona, 85054
Zhi Fong, MD, PhD
Johns Hopkins University
Baltimore, Maryland, 21287
Jin He, MD, PhD
Massachusetts General Hospital
Boston, Massachusetts, 02114
Carlos Fernandez-del Castillo, MD
Mayo Clinic
Rochester, Minnesota, 55905
Cornelius Thiels, D.O., MBA
NYU Langone Health
New York, New York, 10016
Greg Sacks, MD MPH PhD

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.